feedback

Course Director

Edward B. Garon, MD, MS
Edward B. Garon, MD, MS

UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty

Stephen V. Liu
Stephen V. Liu, MD

Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Professor Tony Mok
Professor Tony Mok, MD

The Chinese University of Hong Kong
Hong Kong, China

David L. Rimm
David L. Rimm, MD, PhD

Yale University School of Medicine
New Haven, Connecticut

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2018-Jul-05
Expiration Date:2019-Jul-04
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, top experts in oncology and pathology explore the role and use of current and emerging biomarkers as well as immune-based, cytotoxic, and targeted therapies for lung cancer.

Upon completion of this activity, participants should be better able to:

  • Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches for non–small-cell lung cancer (NSCLC), including cytotoxics, immunotherapies, and targeted agents
  • Describe the role and use of biomarkers that should guide treatment selection in NSCLC and tests for assessing these biomarkers, taking into consideration the principles of precision oncology
  • Determine the best treatment options for each patient with NSCLC from which they are most likely to benefit, guided by appropriate predictive testing, latest clinical evidence, best practice recommendations, and patient needs/preferences, among other relevant factors

Target Audience

The activity will be designed to meet the educational needs of oncologists, pathologists, and other professionals involved in the care of patients with lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 05, 2018 - July 04, 2019
Time to Complete: 120 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Edward B. Garon, MD, MS
Director, Thoracic Oncology Program
Health Sciences Associate Professor
Department of Medicine, Division of Hematology-Oncology
UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb; Dynavax Technologies Corporation; Eli Lilly and Company; Genentech, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc. (All Research Support to Institution).
Edward B. Garon, MD, MS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: biomarker testing platforms, immunotherapies, targeted therapies, chemotherapies, and different treatment combinations for lung cancer.

Faculty

Stephen V. Liu, MD
Associate Professor of Medicine
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Corvus Pharmaceuticals; Genentech, Inc.; Lycera; Merck & Co., Inc.; Molecular Partners; and Pfizer, Inc.
Consultant and/or Advisory Board for AstraZeneca; Bristol-Myers Squibb; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Heron Therapeutics, Inc.; Pfizer Inc.; Taiho Pharmaceutical Co., Ltd.; and Takeda Pharmaceuticals U.S.A., Inc.
Stephen V. Liu, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: biomarker testing platforms, immunotherapies, targeted therapies, chemotherapies, and different treatment combinations for lung cancer.

Professor Tony Mok, MD
Chairman, Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China

Professor Tony Mok, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Merck Sharp & Dohme Corp.; Novartis AG; and Pfizer Inc.
Consultant and/or Advisory Board for ACEA Biosciences, Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb; Eli Lilly and Company; F. Hoffmann-La Roche Ltd/Genentech, Inc.; geneDecode; Merck Serono; Merck Sharp & Dohme Corp.; Novartis AG; OncoGenex Pharmaceuticals; Pfizer Inc.; SFJ Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.
Professor Tony Mok, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: biomarker testing platforms, immunotherapies, targeted therapies, chemotherapies, and different treatment combinations for lung cancer.

David L. Rimm, MD, PhD
Professor of Pathology and Medicine (Medical Oncology)
Director, Yale Pathology Tissue Services
Yale University School of Medicine
New Haven, Connecticut

David L. Rimm, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Cepheid; Gilead; Navigate BioPharma/Novartis Pharmaceuticals Corporation; NextCure, Inc.; PerkinElmer, Inc.; and Ultivue, Inc.
Consultant and/or Advisor for Agendia; Agilent Technologies; AstraZeneca; Biocept, Inc.; Bristol-Myers Squibb; Cell Signaling Technology, Inc.; Cepheid; Merck & Co., Inc.; OptraSCAN, Inc.; PerkinElmer, Inc.; and Ultivue, Inc.
Other Financial or Material Support from PixelGear in the form of equity.
David L. Rimm, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: biomarker testing platforms, immunotherapies, targeted therapies, chemotherapies, and different treatment combinations for lung cancer.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Bayer US and LOXO Oncology, Celgene Corporation, Foundation Medicine, Inc., and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.